Pharmacogenomics of oral antiplatelet drugs

Alfi Yasmina Noorsyahdy, Anthonius de Boer, Olaf H Klungel, Vera H M Deneer

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Pharmacogenomics has been implicated in the response variability of antiplatelet drugs in coronary artery disease (CAD), particularly for aspirin and clopidogrel. A large number of studies and several meta-analyses have been published on this topic, but until recently, there have been no clear conclusions and no definite guidelines on the clinical use of pharmacogenetic testing before prescribing antiplatelet drugs for CAD. In this review, the available evidence is summarized. The most consistent results are on clopidogrel, where CYP2C19 loss-of-function alleles are associated with stent thrombosis events. We recommend to genotype for CYP2C19 loss-of-function alleles in patients with CAD who are to undergo percutaneous coronary intervention and stenting, and to adjust the antiplatelet treatment based on the genotyping results.

Original languageEnglish
Pages (from-to)509-28
Number of pages20
JournalPharmacogenomics
Volume15
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Dive into the research topics of 'Pharmacogenomics of oral antiplatelet drugs'. Together they form a unique fingerprint.

Cite this